Compare
Akebia Therapeutics, Inc. vs Anaptysbio, Inc vs Keros Therapeutics, Inc. vs Puma Biotechnology, Inc.
| Latest fiscal year | Akebia Therapeutics, Inc. AKBA | Anaptysbio, Inc ANAB | Keros Therapeutics, Inc. KROS | Puma Biotechnology, Inc. PBYI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $236.20M | $234.60M | $244.06M | $228.37M |
| Revenue growth (YoY) | +47.5% | +157.0% | n/m | -0.9% |
| Gross margin | 83.3% (computed) | n/a | n/a | 74.5% (computed) |
| Operating margin | 9.9% | 20.4% | 27.7% | 16.3% |
| Net margin | -2.3% | -5.6% | 35.7% | 13.6% |
| Net income | -$5.34M | -$13.23M | $87.01M | $31.11M |
| EPS (Diluted) | -$0.02 | -$0.46 | $2.30 | $0.61 |
| Operating cash flow | $67.99M | $19.70M | $107.50M | $41.80M |
| Free cash flow | $67.70M | $19.61M | $105.95M | $41.73M |
| Cash & equivalents | $184.84M | $238.20M | $287.42M | $29.64M |
| Total assets | $376.56M | $364.39M | $338.02M | $216.30M |
| Total liabilities | $343.95M | n/a | $34.89M | $85.96M |
| Shareholders' equity | $32.61M | $37.21M | $303.13M | $130.34M |
| Return on year-end equity | -16.4% | -35.6% | 28.7% | 23.9% |
| Shares outstanding | 265.42M | 28.02M | 19.54M | 50.41M |
Revenue, most recent five fiscal years
| Fiscal year | Akebia Therapeutics, Inc. | Anaptysbio, Inc | Keros Therapeutics, Inc. | Puma Biotechnology, Inc. |
|---|---|---|---|---|
| Latest | $236.20M Ended 2025-12-31 | $234.60M Ended 2025-12-31 | $244.06M Ended 2025-12-31 | $228.37M Ended 2025-12-31 |
| 1 year earlier | $160.18M Ended 2024-12-31 | $91.28M Ended 2024-12-31 | $3.55M Ended 2024-12-31 | $230.47M Ended 2024-12-31 |
| 2 years earlier | $194.62M Ended 2023-12-31 | $17.16M Ended 2023-12-31 | $151.0K Ended 2023-12-31 | $235.64M Ended 2023-12-31 |
| 3 years earlier | $292.48M Ended 2022-12-31 | $10.29M Ended 2022-12-31 | $0 Ended 2022-12-31 | $228.03M Ended 2022-12-31 |
| 4 years earlier | $211.65M Ended 2021-12-31 | $63.17M Ended 2021-12-31 | $20.10M Ended 2021-12-31 | $253.16M Ended 2021-12-31 |